Tagged as: denosumab

Biosimilar Market Update – Biocon Biologics LTD and Samsung Bioepis

Last week, Biocon Ltd announced the approval of approximately a 150 million USD capital injection from Goldman Sachs.  Dr. Christian Hamacher, CEO, Biocon Biologics, said, “This capital injection by Goldman Sachs will enable us to make prudent investments in R&D, high-quality manufacturing, as well as, establish a global commercial footprint.” …

Read More

Denosumab biosimilar IND approval in China and teriparatide biosimilar launch in South Korea

Shanghai Henlius Biotech (Henlius) recently announced that China’s National Medical Products Administration (NMPA) has approved an investigation new drug (IND) application[1] of HLX14, a denosumab biosimilar.  Denosumab is a recombinant humanized anti-RANKL monoclonal antibody for injection that is approved for the treatment of postmenopausal women with osteoporosis with a high…

Read More